The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities.
Psoriasis
brodalumab
depression
suicidality
Journal
The Journal of clinical and aesthetic dermatology
ISSN: 1941-2789
Titre abrégé: J Clin Aesthet Dermatol
Pays: United States
ID NLM: 101518173
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
ppublish
Résumé
Brodalumab, a first-in-class interleukin-17 (IL-17) receptor blocker, carries a black box warning for suicidal ideation and behavior, yet it is also one of the most powerful biologic agents in our armamentarium. We wish to highlight three patients with moderate-to-severe psoriasis and comorbid depression who were successfully treated with brodalumab. The patients were chosen by an expert panel comprising dermatologists, psychiatrists, and psychologists. Psoriasis disease severity was measured using the Psoriasis Area and Severity Index (PASI) score. All three patients experienced PASI 100 after treatment with brodalumab (N=3). Importantly, depressive symptoms improved or resolved in two out of three patients. One patient, who had a history of psychiatric hospitalizations, required in-patient psychiatric treatment during treatment. The use of brodalumab in patients with psoriasis can provide rapid-onset improvement in both skin and depressive symptoms.
Types de publication
Journal Article
Review
Langues
eng
Pagination
44-48Informations de copyright
Copyright © 2020. Matrix Medical Communications. All rights reserved.
Déclaration de conflit d'intérêts
FUNDING:No funding was provided for this study. DISCLOSURES:Mr. Rivera-Oyola and Drs. Stanger, Litchman, Thibodeaux, Fried, and Han have no relevant conflicts of interest. Drs. Koo, Goldenberg, Hsu, Kircik, Knuckles, Murina, Weinberg, Wu, and Lebwohl have been speakers, advisors, consultants, and/or investigators for Ortho Dermatologics or Valeant.
Références
Am J Clin Dermatol. 2016 Feb;17(1):87-97
pubmed: 26718712
J Drugs Dermatol. 2016 Oct 1;15(10):1192-1196
pubmed: 27741335
Br J Dermatol. 2019 Jan;180(1):116-121
pubmed: 30229872
J Invest Dermatol. 2012 Oct;132(10):2466-2469
pubmed: 22622425
Clin Drug Investig. 2017 May;37(5):439-451
pubmed: 28197901
J Am Acad Dermatol. 2017 Aug;77(2):372-374
pubmed: 28711089
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212
pubmed: 27573025
Clin Dermatol. 2007 Nov-Dec;25(6):606-15
pubmed: 18021899
J Am Acad Dermatol. 2020 Feb;82(2):352-359
pubmed: 31175909
Acta Derm Venereol. 2012 Jan;92(1):67-72
pubmed: 21879243
J Am Acad Dermatol. 2018 Jan;78(1):81-89.e5
pubmed: 28985956
Expert Rev Clin Immunol. 2017 Jan;13(1):27-34
pubmed: 27426230
J Cutan Med Surg. 2016 Jul;20(4):293-303
pubmed: 27207348
J Am Acad Dermatol. 2014 Mar;70(3):512-6
pubmed: 24388724
J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1168-1175
pubmed: 28214371
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
pubmed: 15083780
Br J Dermatol. 2016 Aug;175(2):273-86
pubmed: 26914406
J Eur Acad Dermatol Venereol. 2014 Jun;28(6):763-70
pubmed: 23663069
Cutis. 2017 Feb;99(2):123-127
pubmed: 28319618
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
J Drugs Dermatol. 2016 Mar;15(3):311-6
pubmed: 26954316
Arch Dermatol. 2010 Aug;146(8):891-5
pubmed: 20713823
Br J Dermatol. 2013 Apr;168(4):844-54
pubmed: 23301632
N Engl J Med. 2015 Oct;373(14):1318-28
pubmed: 26422722
Br J Dermatol. 2019 Jan;180(1):108-115
pubmed: 30007069
J Am Acad Dermatol. 2019 Jan;80(1):43-53
pubmed: 30017706
J Am Acad Dermatol. 2019 Jan;80(1):27-40
pubmed: 30017705
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1999-2009
pubmed: 28681405
Autoimmun Rev. 2013 May;12(7):703-8
pubmed: 23207283
J Int Med Res. 2016 Sep;44(1 suppl):61-66
pubmed: 27683142